TY - JOUR
T1 - Scleroderma Induced by Pembrolizumab
T2 - A Case Series
AU - Barbosa, Naiara S.
AU - Wetter, David A.
AU - Wieland, Carilyn N.
AU - Shenoy, Niraj K.
AU - Markovic, Svetomir N.
AU - Thanarajasingam, Uma
PY - 2017/7
Y1 - 2017/7
N2 - Immune checkpoint inhibitors are approved for select cancer treatment and have shown survival benefit in patients with advanced melanoma. Adverse events, including immune-related adverse events, are common and potentially life-threatening. We describe cases of 2 patients with scleroderma (patient 1 had diffuse scleroderma, and patient 2 had limited scleroderma) that developed while they were receiving pembrolizumab therapy for metastatic melanoma. Prompt recognition and treatment of immune-related adverse events may improve tolerance to immune checkpoint inhibitors and contribute to an understanding of the manifesting autoimmune disease.
AB - Immune checkpoint inhibitors are approved for select cancer treatment and have shown survival benefit in patients with advanced melanoma. Adverse events, including immune-related adverse events, are common and potentially life-threatening. We describe cases of 2 patients with scleroderma (patient 1 had diffuse scleroderma, and patient 2 had limited scleroderma) that developed while they were receiving pembrolizumab therapy for metastatic melanoma. Prompt recognition and treatment of immune-related adverse events may improve tolerance to immune checkpoint inhibitors and contribute to an understanding of the manifesting autoimmune disease.
UR - http://www.scopus.com/inward/record.url?scp=85020182824&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85020182824&partnerID=8YFLogxK
U2 - 10.1016/j.mayocp.2017.03.016
DO - 10.1016/j.mayocp.2017.03.016
M3 - Article
C2 - 28599746
AN - SCOPUS:85020182824
SN - 0025-6196
VL - 92
SP - 1158
EP - 1163
JO - Mayo Clinic Proceedings
JF - Mayo Clinic Proceedings
IS - 7
ER -